PubMed:32178765 / 329-534 JSONTXT

Annnotations TAB JSON ListView MergeView

    Inflammaging

    {"project":"Inflammaging","denotations":[{"id":"T4","span":{"begin":0,"end":205},"obj":"Sentence"},{"id":"T4","span":{"begin":0,"end":205},"obj":"Sentence"}],"text":"Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial."}

    yaoziqian_800_3

    {"project":"yaoziqian_800_3","denotations":[{"id":"T4","span":{"begin":0,"end":10},"obj":"CI"},{"id":"T5","span":{"begin":113,"end":132},"obj":"DP"}],"text":"Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial."}

    Zierdiyeerkenaili_800_3

    {"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T2","span":{"begin":0,"end":10},"obj":"CI"},{"id":"T6","span":{"begin":113,"end":132},"obj":"DP"}],"text":"Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial."}